Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736600 | 0.98 | HTT (1.00) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL916128 | 0.95 | NPSR1 (1.00) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL6031412 | 0.81 | GAA (0.68) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL915757 | 0.79 | HTT (0.68) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL3637702 | 0.79 | HTT (0.67) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL4694133 | 0.79 | HTT (0.67) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL4691404 | 0.78 | HTT (0.65) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL2951788 | 0.77 | NPSR1 (0.68) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL14459794 | 0.77 | HTT (0.63) | GAAHTTKMT2ACHEK1TSHR | |
| SCHEMBL939440 | 0.76 | KDM4E (0.64) | GAAHTTKMT2ACHEK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015114663-A1 | NOVEL THIENO [2,3-D]PYRIMIDIN-4(3H)-ONE COMPOUNDS WITH ANTIMYCOBACTERIAL PROPERTIES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-08-06 | — | — | WO | disclosed |
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | GAA 1036/4885HTT 3172/4885KMT2A 2584/4885 |
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | MAVS, SNRPE, LONP1 | GAA 1193/4885HTT 4221/4885KMT2A 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.